The two companies have announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Echosens and Novo Nordisk will collaborate to support additional clinical validation, generation of real-world evidence and adoption of non-invasive diagnostic tests for NASH and work together to increase awareness of the disease and the importance of early diagnosis and management.
“The companies have a shared ambition of doubling diagnostic rates for people living with advanced to severe NASH by 2025.”
The companies have a shared ambition of doubling diagnostic rates for people living with advanced to severe NASH by 2025.
“At Novo Nordisk we are committed to driving change in NASH, to develop new treatment options and advance care for this serious, chronic disease. An important step towards realizing that ambition is to ensure that we can identify the people in need of care,” says Camilla Sylvest, executive vice president for Commercial Strategy & Corporate Affairs at Novo Nordisk. “But we cannot solve this challenge alone and through our partnership with Echosens, we hope to leverage our complementary skills to meet the needs of patients, healthcare providers and other stakeholders striving to address this ‘silent’ epidemic.”
Photo of Camilla Sylvest: Novo Nordisk
